Rthp-39. survival outcome of long-term responders to fractionated versus single-dose stereotactic radiosurgery (srs)
Treatment of brain metastases with fractionated stereotactic radiosurgery (F-SRS) is predicated on intent to reduce radiation toxicity without compromising local control. In patients with large brain metastases, F-SRS has been suggested to have improved local control compared to single-fraction stereotactic radiosurgery (S-SRS) with acceptable toxicity. The differences, though, between patients who undergo S-SRS and F-SRS that survive well beyond the one-year time frame are still unclear. Here we present a retrospective review of brain-metastatic lung and breast cancer patients that survived at least one year from initial ...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Vuong, W., Goldstein, L., Radany, E., Chen, M., Badie, B., Dandapani, S. Tags: RADIATION THERAPY Source Type: research
Rthp-38. improving access to radiation: a retrospective analysis to identify barriers to treatment among high grade glioma patients in the bronx
CONCLUSIONS:Among MMC’s diverse and historically under-represented patients, women and non-English speakers were less likely to initiate RT as compared to men and English speakers. Further QI initiatives are needed to better understand these differences and improve access for all. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Purswani, J., Massad, N., Lasala, P., Ohri, N., Welch, M. Tags: RADIATION THERAPY Source Type: research
Rthp-37. rates and impact of compliance with tumor treating fields therapy in a glioma cohort
Tumor-treating fields (TTF) was approved in 2011 for recurrent glioblastomas then for adjuvant therapy in 2016 given the significant survival benefit shown in recent trials. Since 12/2012, 46 patients were treated with TTF for recurrent or newly diagnosed gliomas at Columbia University. We detail demographics, compliance rates and outcomes in this retrospective cohort. Of 42 treated patients with available compliance data, 16 (38%) were women and 2 (4.8%), 4 (9.5%) and 36 (85.7%) had WHO grade II, III and IV gliomas, respectively. Median age at diagnosis was 56 (23-84) years. TTF was used at recurrence in 33 (79%), with a ...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Odia, Y., Schulte, J., Iwamoto, F. Tags: RADIATION THERAPY Source Type: research
Rthp-36. contribution of dwi and radiation therapy dose distribution to response assessment in patients with recurrent glioma treated with reirradiation
CONCLUSION:Documenting progression following reRT remains challenging. In our series, perfused enhancement outside of the reRT field was associated with rapid progression, while increased enhancement or T2 FLAIR volume did not necessarily result in progression. Progression post reRT will need to be based on close examination of DWI and reRT isodose lines in conjunction with clinical decline. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Krauze, A., Cheng, J. Tags: RADIATION THERAPY Source Type: research
Rthp-35. impact of tumor treatment field array on proton beam dose distribution and image guidance in the treatment of cns malignancies
CONCLUSIONS:Use of the TTF system concurrently with proton beam therapy may be possible with alterations in treatment planning and array placement on radiotherapy treatment days. Further clinical study is warranted to determine feasibility and whether an additional clinical effect is possible. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Morgan, H., Wilkinson, J. B., Maynard, M., Dugas, J., Wu, H., Bonnette, D., Rosen, L., Chen, K. Tags: RADIATION THERAPY Source Type: research
Rthp-34. placement of scalp electrodes (novo ttf) does not significantly change radiation dosimetry when delivering cranial intensity modulated radiation therapy (imrt)
CONCLUSION:In a cranial radiation phantom model, the presence of NovoTTF transducer arrays does not impact radiation dosimetry. The impact would be even less in actual patient treatment due to frequent change of arrays with slight shift in placement. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Shukla, G., Palmer, J., Li, T., Lockamy, V., Peng, C., Shi, W. Tags: RADIATION THERAPY Source Type: research
Rthp-33. outcomes after stereotactic radiation therapy for primary cns lymphoma
CONCLUSION:Stereotactic radiation therapy may provide favorable local control in patients with refractory PCNSL at high risk with WBRT. Prospective trial is warranted to validate the efficacy of such an approach. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Shukla, G., Palmer, J., Glass, J., Kim, L., Shi, W. Tags: RADIATION THERAPY Source Type: research
Rthp-32. reconsidering radioresistance: linac-based stereotactic radiosurgery for intracranial metastases from melanoma and renal cell carcinoma
CONCLUSION:LINAC-based SRS for melanoma and RCC brain metastases was well-tolerated with acceptable toxicity. There is a trend toward improved FFLF for patients with RCC compared to those with melanoma. FFLF was lower than other histologies from historical reports, but consistent with published data for melanoma and RCC. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Feng, C., Lemons, J., Raleigh, D. R., Surucu, M., Farrey, K., Yamini, B., Chmura, S. J., Golden, D. W. Tags: RADIATION THERAPY Source Type: research
Rthp-31. low grade glioma malignant transformation (mt): clinical outcomes and prognostic factors in temozolomide era
CONCLUSIONS:Outcomes of MT LGGs are similar to de novo high grade gliomas, regardless of pathologic confirmation. Our series suggests that temozolomide may increase the risk of MT and 1p19q status is not impactful. These results need to be validated in an independent cohort. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Murphy, E., Leyrer, C. M. L., Parsons, M., Suh, J., Chao, S., Yu, J., Jia, X., Peereboom, D., Stevens, G., Ahluwalia, M. S. Tags: RADIATION THERAPY Source Type: research
RTHP-30. ENHANCED THERAPEUTIC BENEFITS OF TUMOR TREATING FIELDS (TTFIELDs) ON SUPERFICIALLY LOCATED GLIOBLASTOMA MULTIFORME (GBM)
CONCLUSION:Tumor depth may be an independent prognostic factor for patients receiving TTField treatment for GBMs, with superficially located GBMs having the greatest improvement in PFS and OS. We plan to confirm these preliminary findings in a larger data set. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Harris, D., Kumar, V. Tags: RADIATION THERAPY Source Type: research
RTHP-29. COMPLIANCE AND DURATION OF TREATMENT WITH TUMOR TREATING FIELDS (TTFIELDs) IN ADJUVANT TREATMENT FOR NEWLY DIAGNOSED GLIOBLASTOMAS (GBMs) IMPROVES PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS)
CONCLUSIONS:Increased compliance positively correlated with improved OS; duration of treatment positively correlated with PFS and OS. Extent of resection improved duration of treatment, PFS and OS, suggesting that patients with aggressive resections are the best candidates for treatment with TTFields. These results will need to be verified in a larger data set. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Kumar, V., Harris, D. Tags: RADIATION THERAPY Source Type: research
RTHP-27. PHASE I/II STUDY OF DDFPe AS A RADIOSENSITIZER IN GLIOBLASTOMA
DISCUSSION:DDFPe is a promising oxygen therapeutic for reversing tumor hypoxia and merits Phase II study. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Unger, E., Mason, R., Zhou, H., Sellenger, M., Ruben, J., Lickliter, J., Longacre, O. Tags: RADIATION THERAPY Source Type: research
Rthp-26. evaluating a single isocenter radiation approach to treat multiple brain metastases (bm) with stereotactic radiosurgery (srs): impact of lesion number, location and volume on treatment plan results
In an attempt to diminution the sequelae of whole brain irradiation, multiple BM are more frequently approached with SRS rather than whole brain irradiation. However, the individual treatment of each lesion with a multi-isocenter, serial approach is cumbersome and time consuming. We elected to investigate a single-isocenter volumetric modulated arc therapy (VMAT) planning and treatment technique for radiosurgical treatment of multiple BM. The emphasize was placed on tumor number, size, volume and location and its impact on the treatment plan. Treatment plan data of 10 patients with multiple BM were selected for a prospecti...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Kanner, A. A., Corn, B. W. Tags: RADIATION THERAPY Source Type: research
Rthp-25. superior prognostic value of cumulative intracranial tumor volume (citv) relative to largest intracranial tumor volume (litv) for stereotactic radiosurgery treated brain metastasis patients
CONCLUSION:After accounting for age, KPS, status of extracranial disease, and the number of brain metastasis, CITV offer superior prognostic value relative to LITV for SRS-treated BM patients in two independent cohorts that summed to ~6,000 patients. (Source: Neuro-Oncology)
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Chen, C., Hirshman, B., Wilson, B., Amaan, M., Proudfoot, J., Koiso, T., Nagano, O., Serizawa, T., Yamamoto, M. Tags: RADIATION THERAPY Source Type: research
Rthp-24. pseudoprogression after proton vs. photon therapy in patients with oligodendroglioma
Proton therapy is increasingly used for treatment of primary brain tumors. Recent concern has emerged regarding potentially higher rates of pseudoprogression, the development of new enhancement within the radiation field, after proton therapy compared to photon therapy. Pseudoprogression can be difficult to distinguish from true progression and is poorly described for patients with oligodendroglioma. We retrospectively reviewed 68 patients with grade 2 or 3 oligodendroglioma treated with proton (n = 27) or photon (n = 41) therapy. All patients were treated between 2004 and 2015 and had a minimum of 6&nb...
Source: Neuro-Oncology - November 6, 2016 Category: Cancer & Oncology Authors: Bronk, J. K., Guha-Thakurta, N., Mahajan, A., Grosshans, D. R., McGovern, S. L. Tags: RADIATION THERAPY Source Type: research
